Scribe Therapeutics
T. C. Stevenson Keller has a diverse work experience. In 2022, they began working as an Investigator in In Vivo Biology at Scribe Therapeutics. From 2019 to 2022, they worked as a Postdoctoral Researcher at Penn Medicine, University of Pennsylvania Health System. From 2014 to 2019, they were a Ph.D. Candidate in Molecular Physiology and Biological Physics at the University of Virginia. From 2016 to 2017, they were a Visiting Researcher at the University of Düsseldorf, working in the Institute of Experimental Cardiology.
T. C. Stevenson Keller obtained a B.S. in Physics from Davidson College between 2010 and 2014. Following this, Keller went on to obtain a Doctor of Philosophy (Ph.D.) in Molecular Physiology and Biological Physics from the University of Virginia between 2014 and 2019.
Scribe Therapeutics
1 followers
Scribe is focused on the engineering, delivery, and development of next-generation CRISPR molecules to rewrite and repair the underlying cause of genetic disorders.